Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

  • Revenue in CHF (TTM)47.21bn
  • Net income in CHF8.23bn
  • Incorporated1996
  • Employees109.00k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
NOVN:SWX since
Arctos Medical AGDeal completed21 Sep 202121 Sep 2021Deal completed0.43%--
Cadent TherapeuticsAnnounced17 Dec 202017 Dec 2020Announced-3.70%770.00m
Data delayed at least 15 minutes, as of Oct 22 2021 16:32 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Takeda Pharmaceutical Co Ltd27.01bn3.48bn40.91bn47.10k11.700.95925.111.51273.81273.812,124.963,339.330.26481.304.1571,032,620.003.411.974.012.4470.1868.6412.897.100.99455.310.4568124.20-2.8412.09749.9036.2222.750.00
Bayer AG44.48bn-8.07bn50.65bn99.44k--1.56--1.14-7.70-2.7342.4530.930.35011.953.18418,764.70-6.35-0.9407-8.72-1.2052.7260.72-18.13-2.480.799511.420.569---4.93-2.12-751.15---0.7993-4.06
Chugai Pharmaceutical Co Ltd7.17bn2.07bn52.06bn7.56k24.635.79--7.26155.92155.92539.79663.310.71331.573.44117,527,200.0020.6012.7624.9015.2166.2357.6728.8819.272.91----46.7614.689.5536.2928.5719.4425.98
Novartis AG47.21bn8.23bn190.80bn109.00k21.343.5013.824.043.623.6220.7722.130.41622.156.43446,291.707.256.419.538.0170.7269.3917.4317.790.5635--0.397981.092.62-0.183813.022.84-5.914.69
Roche Holding AG59.76bn14.02bn312.79bn101.47k21.908.0416.085.2316.2516.2569.2444.270.71032.285.12588,922.3017.6214.8226.0722.0871.1571.3924.8020.920.910680.510.26666.01-5.113.915.9110.0313.842.36
Data as of Oct 22 2021. Currency figures normalised to Novartis AG's reporting currency: Swiss Franc CHF

Institutional shareholders

14.78%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 202158.00m2.38%
UBS Asset Management Switzerland AGas of 31 Dec 202056.76m2.33%
Norges Bank Investment Managementas of 31 Dec 202056.45m2.32%
Wellington Management Co. LLPas of 08 Oct 202141.28m1.70%
BlackRock Fund Advisorsas of 07 Oct 202135.92m1.48%
Credit Suisse Asset Management (Schweiz) AGas of 30 Sep 202131.82m1.31%
Z�rcher Kantonalbank (Investment Management)as of 30 Jun 202122.89m0.94%
Dodge & Coxas of 30 Jun 202121.11m0.87%
Capital Research & Management Co. (World Investors)as of 30 Jun 202120.30m0.83%
Magellan Asset Management Ltd.as of 30 Jun 202115.32m0.63%
More ▼
Data from 31 Dec 2020 - 30 Sep 2021Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.